Innovator IBD Financial Statements From 2010 to 2024
| FFTY Etf | USD 29.84 0.67 2.30% |
Check Innovator IBD financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innovator IBD's main balance sheet or income statement drivers, such as , as well as many indicators such as . Innovator financial statements analysis is a perfect complement when working with Innovator IBD Valuation or Volatility modules.
Innovator |
Innovator IBD 50 ETF Price To Sales Analysis
Innovator IBD's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Innovator IBD Price To Sales | 3.74 X |
Most of Innovator IBD's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovator IBD 50 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Innovator IBD 50 has a Price To Sales of 3.74 times. This is much higher than that of the Innovator ETFs family and significantly higher than that of the Mid-Cap Growth category. The price to sales for all United States etfs is notably lower than that of the firm.
Innovator IBD 50 Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innovator IBD's current stock value. Our valuation model uses many indicators to compare Innovator IBD value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innovator IBD competition to find correlations between indicators driving Innovator IBD's intrinsic value. More Info.Innovator IBD 50 is one of the top ETFs in price to earning as compared to similar ETFs. It also is one of the top ETFs in price to book as compared to similar ETFs fabricating about 0.15 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Innovator IBD 50 is roughly 6.55 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innovator IBD's earnings, one of the primary drivers of an investment's value.About Innovator IBD Financial Statements
Innovator IBD investors use historical fundamental indicators, such as Innovator IBD's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Innovator IBD. Please read more on our technical analysis and fundamental analysis pages.
The fund will normally invest at least 80 percent of its net assets in securities that comprise the index. Innovator Ibd is traded on NYSEARCA Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innovator IBD 50 offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innovator IBD's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innovator Ibd 50 Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Innovator Ibd 50 Etf:Check out the analysis of Innovator IBD Correlation against competitors. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
The market value of Innovator IBD 50 is measured differently than its book value, which is the value of Innovator that is recorded on the company's balance sheet. Investors also form their own opinion of Innovator IBD's value that differs from its market value or its book value, called intrinsic value, which is Innovator IBD's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innovator IBD's market value can be influenced by many factors that don't directly affect Innovator IBD's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innovator IBD's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innovator IBD is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innovator IBD's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.